CT/NG Testing Market by Product (Assays, Kits & Analyzers), Test Type (Laboratory, Point-of-care Testing), Technology (INAAT, PCR, Immunodiagnostics), End User (Diagnostic Labs, Hospitals & Clinics) & Region - Global Forecast to 2028
Updated on : July 04, 2023
The global CT/NG testing market in terms of revenue was estimated to be worth $1.7 billion in 2023 and is poised to reach $2.7 billion by 2028, growing at a CAGR of 8.6% from 2023 to 2028. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. Market growth is largely driven by the increasing prevalence of CT/NG infections and the growing investments and funding for R&D in CT/NG diagnosis.
On the other hand, the unfavorable reimbursement scenario and the high cost of instruments and kits may restrain the growth of this market to a certain extent.
Attractive Opportunities in the CT/NG testing Market
To know about the assumptions considered for the study, Request for Free Sample Report
CT/NG testing Market Dynamics
DRIVER: Increasing investments and funding to drive market growth
Government initiatives, schemes, or funding activities that support and promote innovation and development provide growth opportunities in the CT/NG testing market. These financial incentives and support systems enable companies to invest in research and development, infrastructure, and the production of advanced diagnostic technologies. By facilitating access to funds, the manufacturers are encouraged to push the boundaries of CT/NG testing, leading to breakthrough innovations in disease detection, monitoring, and personalized medicine. For instance, in April 2022, the Chiricahua Community Health Centers, Inc. (CCHCI) stated that it was collaborating with The Body Agency Collective (TBAC) and Visby Medical, Inc., to improve sexually transmitted infection (STI) diagnosis and treatment in observance of National STD Awareness Week. This project will utilize a new PCR diagnostic device which is the Sexual Health Click Test, and it detects three of the most common and curable STIs in women – gonorrhea, chlamydia, and trichomoniasis.
RESTRAINT: High cost of instruments
The entire cost is increased by the variable costs of the required reagents, instruments and those set up by the suppliers. Maintenance and insurance, laboratory supervision, and administrative costs (including rent, office space and administration) are extra costs as well. Only major hospitals and reference laboratories with healthy capital budgets may be able to afford the huge amount of diagnostic equipment. On the other hand, small laboratories, physicians’ offices, and private or individual practitioners encounter capital constraints and therefore, can find it difficult to afford a big or huge instruments and analyzer. Generally, a CT/NG testing kits and instruments can cost between USD 2,000 and USD 80,000. These, costly requirements might hinder the growth of the CT/NG (STI) testing market.
OPPORTUNITY: Growing opportunities in emerging countries
Emerging economies such as India, South Korea, Brazil, and Mexico offer significant growth opportunities to players operating in the CT/NG testing market. This can be attributed to the low regulatory barriers, improvements in healthcare infrastructure, growing patient population, rising prevalence of infections, and rising healthcare expenditure. Moreover, the regulatory policies in some of these countries are more adaptive and business-friendly than those in developed countries. For example, according to the OECD, the purchasing power of the growing middle-class population is expected to increase to 65% by 2022 from 23% in 2009. This is expected to result in the increasing medical needs of the middle-class population, which will favor market growth. Moreover, as markets in the US and Europe mature, most players will shift their focus to emerging markets. The high investments in healthcare and life science research in emerging markets play an essential role in upgrading laboratory infrastructure in these countries. This, in turn, supports the installation of diagnostic systems in laboratories and leads to the growing adoption of CT/NG testing (CT/NG testing).
CHALLENGE: Operational barriers and shortage of skills across major markets
Clinical laboratories are still developing in all; technicians must overcome practical obstacles to ensure efficient sample collection, storage, and transportation. To prevent cross-contamination and maintain efficient time management, laboratory areas must also be redesigned to conduct particular diagnostic procedures used for pathogen detection. This causes maintenance and operation of modern CT/NG devices, particularly those equipped to handle a single sample type, to significantly increase in cost.
Furthermore, clinical laboratories need to embrace cutting-edge technologies capable of quick sample diagnosis due to due to rapid mutation of micro-organisms and the rise in epidemic outbreak. However, the overall adoption of modern molecular diagnostics technologies has hampered, particularly in emerging economies, by the lack of experienced and technically educated laboratory staff.
CT/NG Testing Ecosystem/Market Map
Assays & kits segment accounted for the largest share of the CT/NG Testing Industry in 2022, by product
Based on product, the global CT/NG testing market is segmented into two segments namely, assays & kits and instruments/analyzers. In 2022, the assays & kits segment accounted for the largest share of the CT/NG testing market. The high share of this segment is attributed to its in-demand and continuous need for diagnosis and treatment. Due to recurrent purchasing it is a high cost product and thereby adds to the segment growth.
Lab tests segment accounted for the largest share in the CT/NG testing industry in 2022, by testing type
The global CT/NG testing market is categorized into lab tests and PoC tests based on test type. In 2022, the lab tests segment held the largest share in the CT/NG testing market, categorized by test type. The growth of this segment can be attributed to factors such as the growing demand for automation in laboratory settings and the increasing incidence of various infectious diseases.
Lab tests are equipped with higher sensitivity and specificity compared to PoC tests. Having a controlled laboratory environment ensures more accurate and sensitive measurements, thereby reducing the chances of false-negative or false-positive results. Another advantage of lab tests is the ability to process a more number of samples simultaneously. Such factors are expected to fuel the growth of this segment.
North America accounted for the largest share of the CT/NG testing industry in 2022
The CT/NG testing market is segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. In 2022, North America emerged as the leading contributor, claiming the largest portion of the market share in the CT/NG testing industry. North America has been at the forefront of technological advancements in the field of diagnostics. The region has a robust infrastructure for R&D, which has led to the rapid adoption of innovative diagnostic techniques and platforms. Also, North America houses several major companies operating in the CT/NG testing sector. These companies have significant expertise, resources, and established distribution networks, which contribute to the region's market dominance. Examples of prominent CT/NG testing companies in North America include Hologic, Inc. (US), PerkinElmer, Inc. (US), Abbott Laboratories (US), and Thermo Fisher Scientific Inc. (US).
To know about the assumptions considered for the study, download the pdf brochure
The major players in CT/NG Testing Market are F. Hoffmann-La Roche Ltd. (Switzerland), Hologic, Inc. (US), Thermo Fisher Scientific Inc. (US), Abbott Laboratories (US), Bio-Rad Laboratories, Inc. (US), Siemens Healthineers AG (Germany), Danaher (US), Becton, Dickinson and Company (US). The market leadership of these players stems from their comprehensive product portfolios and expanding global footprint. These dominant market players possess several advantages, including strong marketing and distribution networks, substantial research and development budgets, and well-established brand recognition.
Scope of the CT/NG Testing Industry
|
Report Metric |
Details |
|
Market Revenue by 2023 |
$1.7 billion |
|
Projected Revenue by 2028 |
$2.7 billion |
|
Revenue Rate |
Poised to Grow at a CAGR of 8.6% |
|
Market Driver |
Increasing investments and funding to drive market growth |
|
Market Opportunity |
Growing opportunities in emerging countries |
This report categorizes the CT/NG testing market to forecast revenue and analyze trends in each of the following submarkets:
By Product
- Assays & Kits
- Instruments/Analyzers
By Testing Type
- Lab Tests
- PoC Tests
By Technology
- Isothermal Nucleic Acid Amplification Technology
- Polymerase Chain Reaction
- Immunodiagnostics
- Other Technologies
By End User
- Diagnostic Laboratories
- Hospitals & Clinics
- Other End Users
By Region
-
North America
- US
- Canada
-
Europe
- Germany
- UK
- France
- Italy
- Spain
- Rest of Europe
-
Asia Pacific
- China
- Japan
- India
- Rest of Asia Pacific
- Latin America
- Middle East & Africa
Recent Developments in CT/NG Testing Industry
- In February 2023, Thermo Fisher Scientific Inc. (US) acquired TIB Molbiol (Germany), to expand its PCR test portfolio with a wide range of assays for infectious diseases.
- In May 2022, Hologic, Inc. (US) acquired Diagenode (US), a developer and manufacturer of molecular diagnostic assays and epigenetics products. This acquisition will further strengthen the company’s molecular diagnostics business by expanding its international capabilities and improving its regional time-to-market.
- In December 2021, Hologic, Inc. (US) launched Panther Trax for high-volume molecular testing.
- In September 2020, QIAGEN (Netherlands) Acquired NeuMoDx Molecular (US) to expand QIAGEN’s portfolio of automated molecular testing solutions based on the proven PCR technology
Frequently Asked Questions (FAQ):
What is the projected market revenue value of the global CT/NG testing market?
The global CT/NG testing market boasts a total revenue value of $2.7 billion by 2028.
What is the estimated growth rate (CAGR) of the global CT/NG testing market?
The global CT/NG testing market has an estimated compound annual growth rate (CAGR) of 8.6% and a revenue size in the region of $1.7 billion in 2023.
To speak to our analyst for a discussion on the above findings, click Speak to Analyst
The objective of the study is analyze the key market dynamics such as drivers, opportunities, challenges, restraints, and key player strategies. To track companies developments such as acquisitions, product launches, expansions, agreements and partnerships of the leading players, the competitive landscape of the CT/NG testing market to analyzes market players on various parameters within the broad categories of business and product strategy. Top-down and bottom-up approaches were use to estimate the market size. To estimate the market size of segments and subsegments the market breakdown and data triangulation were used.
The four steps involved in estimating the market size are
Secondary Research
In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to identify and collect information for this study.
Primary Research
In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources were mainly industry experts from the core and related industries and preferred suppliers, manufacturers, distributors, service providers, technology developers, researchers, and organizations related to all segments of this industry’s value chain. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, to obtain and verify the critical qualitative and quantitative information as well as assess prospects.
The following is a breakdown of the primary respondents:
Breakdown of Primary Participants:
Note 1: Others include sales managers, marketing managers, and product managers.
Note 2: Companies are classified into tiers based on their total revenues. As of 2022, Tier 1 = >USD 100 million, Tier 2 = USD 10 million to USD 100 million, and Tier 3 = <USD 10 million.
To know about the assumptions considered for the study, download the pdf brochure
|
COMPANY NAME |
DESIGNATION |
|
Abbott |
Marketing Manager |
|
F. Hoffmann-La Roche Ltd |
Senior Product Manager |
|
Danaher |
Marketing Manager |
Market Size Estimation
Both top-down and bottom-up approaches were used to estimate and validate the CT/NG testing market's total size. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
- The key players in the industry have been identified through extensive secondary research
- The revenues generated by leading players operating in the CT/NG testing market have been determined through primary and secondary research
- All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources
Global CT/NG testing Market Size: Bottom Up Approach
To know about the assumptions considered for the study, Request for Free Sample Report
Global CT/NG testing market Size: Top-Down Approach
Data Triangulation
After arriving at the overall market size applying the process mentioned above, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Market Definition
Chlamydia trachomatis/Neisseria gonorrhoeae (CT/NG) infections are the most common sexually transmitted diseases (STDs) worldwide. CT/NG testing is a technique used to identify and analyze nucleic acids at a molecular level using molecular diagnostics and immunodiagnostics methods. This technique assesses an individual’s genetic makeup to identify a predisposition to the disease or condition and diagnose it.
Key Stakeholders
- Senior Management
- End User
- Finance/Procurement Department
- R&D Department
Report Objectives
- To define, describe, segment, and forecast the global CT/NG testing market, by product, testing type, technology, end user, and region
- To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
- To analyze the micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall CT/NG testing market
- To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
- To forecast the size of the market segments with respect to five regions, namely, North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
- To profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies2
- To track and analyze company developments such as product launches & approvals, partnerships, acquisitions, agreements, and other developments
- To benchmark players within the market using the proprietary Competitive Leadership Mapping framework, which analyzes market players on various parameters within the broad categories of business and product excellence
Available Customizations
MarketsandMarkets offers the following customizations for this market report
Country Information
- Additional country-level analysis of the CT/NG testing market
Company profiles
- Additional five company profiles of players operating in the CT/NG testing market.
Product Analysis
- Product matrix, which provides a detailed comparison of the product portfolio of each company in the CT/NG testing market
Growth opportunities and latent adjacency in CT/NG Testing Market